Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Comparing two pacing methods to prevent persistent atrial fibrillation

Official title: Physiological Ventricular Pacing Versus Managed Ventricular Pacing for Persistent Atrial Fibrillation Prevention in Patients With Prolonged Atrioventricular Interval: a Multicenter RCT

Run by Quovadis Associazione · NCT05367037 · Data updated 2026-11-12

This study is testing whether a new way of pacing the heart can help people with certain heart conditions avoid long-term atrial fibrillation.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment640 (estimated)
SponsorQuovadis Associazione
Academic / other
Locations1 site (Rovigo, Veneto)
StatusRecruiting
StartedJuly 27, 2022
Main results expectedDecember 2028
Study endsDecember 2028
Registry record updatedMay 11, 2025
Trial IDNCT05367037 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients aged 18 and older with prolonged atrioventricular intervals and indications for pacemaker implantation due to sinus node disease or paroxysmal second-degree AV block.

Probably not a fit

Patients who may not benefit include those with severe valvular heart disease, a history of long-standing persistent atrial fibrillation, or those requiring other cardiac devices.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, prospective, randomized study aims to evaluate the effectiveness of physiological ventricular pacing compared to managed ventricular pacing in preventing persistent atrial fibrillation in patients with prolonged atrioventricular intervals. Participants will be randomly assigned to one of the two pacing methods, with the primary endpoint assessed by the pacemaker's internal diagnostic algorithm. The study focuses on patients with sinus node disease or paroxysmal second-degree AV block who require pacing. If successful, this approach could significantly reduce the occurrence of persistent atrial fibrillation in this patient population.

Why it matters

Potential benefit: If successful, this study could provide a more effective pacing method that reduces the risk of persistent atrial fibrillation in patients with specific heart conditions.

How similar studies have gone: While this approach is innovative, similar studies have shown promise in improving pacing techniques, suggesting potential for success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

18 years older patients, able to express Informed Consent, with prolonged atrioventricular interval (PR\>180 ms) and one of the following indications for PM implantation according to current guidelines:

* Sinus node disease.
* Paroxysmal type1or 2 second-degree AV-block.

Exclusion Criteria:

* Candidacy for implantable cardioverter-defibrillator or cardiac resynchronization therapy device implantation.
* Severe grade mitral or aortic regurgitation/stenosis.
* Atrial fibrillation ablation (left pulmonary veins).
* Cardiac surgery \< 3 months before PM implantation.
* History of long-standing persistent AF.
* Permanent third-degree AV block.
* Participation in another clinical trial in the past 3 months.
* Pregnancy or intention to become pregnant.
* Life expectancy of \< 3 years.

Where it's running

  • Elettrofisiologia, Cardiologia, Ospedale di Rovigo
    Rovigo, Veneto, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.